Formulation: A crystalline solid
Formal Name: N-(1-oxopentyl)-N-[[2’-(2H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-L-valine compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1’-biphenyl]-4-pentanoate, sodium salt, hydrate (2:2:6:5)
Purity: ≥98% (1:1 ratio of Valsartan and AHU377)
Formula Markup: C24H29N5O3 • C24H29NO5 • 5/2H2O • 3Na
Formula Weight: 916
Shelf life (days): 1460
CAS Number: 936623-90-4
Notes: LCZ696 is a dual angiotensin II receptor antagonist and neprilysin inhibitor that is a combination of the nonpeptide angiotensin II receptor antagonist valsartan (Item No. 14178) and AHU377 (Item No. 21473), a prodrug of LBQ657 (Item No. 19829), which is an inhibitor of the zinc metallopeptidase neprilysin.{21001,31813},{31812} LCZ696 (2-60 mg/kg) induces a dose-dependent decrease in mean arterial pressure in rats expressing human renin and angiotensinogen, a double-transgenic model for angiotensin II-dependent hypertension.{31812} Formulations containing LCZ696 have been used in the treatment of chronic heart failure.
English
Deutsch
